In contrast, these markers decreased markedly in the huMSCs-exo treatment group (Fig. 1d, HBDH: CLP 12 h + exo group 647 ± 162.2 versus CLP 12 h group 1210 ± 246.2, p = 0.0001; CK: CLP 12 h + exo group 6884 ± 1051 versus CLP 12 h group 14,238 ± 2293, p < 0.0001; cTnI: CLP 12 h + exo group 70.66 ± 18.4 versus CLP 12 h group 115.1 ± 30.8, p = 0.0063), which indicated that treatment with huMSCs-exo effectively mitigated sepsis-induced cardiomyocyte injury. The gene discussed is TNNI3; the disease is Sepsis.